AIM
AIM
AMEX · Biotechnology

Aim Immunotech Inc

$0.37
+0.01 (+3.00%)
As of Jun 24, 10:17 PM ET ·
Financial Highlights (FY 2026)
Revenue
1.51M
Net Income
-239,077,261
Gross Margin
-45.4%
Profit Margin
-15,861.4%
Rev Growth
-14.5%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin -45.4% -45.4% 50.8% 50.8%
Operating Margin -13,254.5% -11,929.1% -19.6% -21.6%
Profit Margin -15,861.4% -15,068.3% -22.2% -17.1%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 1.51M 1.76M 1.31M 1.61M
Gross Profit -685,475 -802,100 667.2K 816.8K
Operating Income -199,904,858 -210,524,657 -257,805 -347,025
Net Income -239,077,261 -251,778,065 -292,011 -275,194
Gross Margin -45.4% -45.4% 50.8% 50.8%
Operating Margin -13,254.5% -11,929.1% -19.6% -21.6%
Profit Margin -15,861.4% -15,068.3% -22.2% -17.1%
Rev Growth -14.5% -14.5% +20.5% -9.2%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 1.16M 1.06M
Total Equity 1.39M 1.56M
D/E Ratio 0.83 0.68
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -199,151,575 -221,383,098 -341,169 -390,753
Free Cash Flow -173,511 -203,411